Elsevier

Neuroscience

Volume 48, Issue 2, May 1992, Pages 485-490
Neuroscience

Serotonin is a directly-acting hyperalgesic agent in the rat

https://doi.org/10.1016/0306-4522(92)90508-YGet rights and content

Abstract

In this study, we have investigated serotonin hyperalgesia employing the mechanical paw withdrawal nociceptive threshold test in the rat. Intradermally injected serotonin was found to produce a dose-dependent hyperalgesia that was not attenuated by procedures which eliminate the known indirect mechanisms of hyperalgesia such as sympathectomy, polymorphonuclear leukocyte depletion or cyclooxygenase inhibition. In addition, the latency to onset of serotonin hyperalgesia is extremely short, with maximal hyperalgesia observed in less than 1 min, a similar temporal onset to direct-acting hyperalgesic agents such as prostaglandin E2. The results suggest, therefore, that the hyperalgesic effects of serotonin in our animal model are exerted by direct action on primary afferent neurons.

Only the intradermal injection of selective serotonin (5-hydroxytryptamine; 5-HT) agonists for the 1A receptor subset (5-HT1A), (±)-2-dipropylamino-8-hydroxy-1,2,3,4-tetrahydronaphthaline hydrobromide and N,N-dipropyl-5-car☐amido-tryptamine maleate, produced dose-dependent hyperalgesia. No hyperalgesia was seen after 5-HT1B, CGS-120666 maleate andm-trifluoromethylphenyl-perazine hydrochloride; 5-HT2+1C, alpha methyl 5HT and (±)-1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane HCl; or 5-HT3,2-methyl-5-hydroxytryptamine maleate and phenylbiguanide, agonists. Similarly, only the 5-HT1A antagonists, spiroxatrine and spiperone, attenuated the hyperalgesia induced by intradermally injected serotonin. 5-HT2+1C antagonists, mesulergine and ketanserin, and 5-HT3 antagonists, quipazine and 3-tropanyl-indole-3-car☐ylate, did not significantly attenuate 5-HT hyperalgesia.

We conclude that serotonin produces hyperalgesia by a direct action on the primary afferent neuron via the 5-HT1A subset of serotonin receptors.

References (66)

  • JanowskyA. et al.

    Characterization of neurotransmitter receptor-mediated phosphatidylinositol hydrolysis in the rat hippocampus

    Life Sci.

    (1984)
  • JuanH.

    Prostaglandins as modulators of pain

    Gen. Pharmac.

    (1978)
  • LeysenJ.E. et al.

    Receptor binding profile of R41468 a novel antagonist at 5HT2 receptors

    Life Sci.

    (1981)
  • MiddlemissD.N. et al.

    8-Hydroxy-2-(di-n-propylamino)-tetralin discriminates between subtypes of the 5HT1 recognition site

    Eur. J. Pharmac.

    (1983)
  • MoritaK. et al.

    5-Hydroxytryptamine effects on the soma of bullfrog primary afferent neurons

    Neuroscience

    (1987)
  • NealeR.F. et al.

    Biochemical and pharmacological characterization of CGS-12066B

    Eur. J. Pharmac.

    (1987)
  • NelsonD.L. et al.

    [3H] Spiroxatrine labels a serotonin 1A-like site in the rat hippocampus

    Life Sci.

    (1987)
  • NelsonD.L. et al.

    Spiroxatrine: a selective serotonin 1A receptor antagonist

    Eur. J. Pharmac.

    (1986)
  • PazosA. et al.

    The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site

    Eur. J. Pharmac.

    (1984)
  • PeroutkaS.J.

    5-Hydroxytryptamine receptor subtypes: molecular, biochemical and physiological characterization

    Trends Neurosci.

    (1988)
  • PeroutkaS.K. et al.

    [3H] Quipazine labels 5-HT3 recognition sites in rat cortical membranes

    Eur. J. Pharmac.

    (1988)
  • RichardsonB.P. et al.

    The pharmacology and function of 5-HT3 receptors

    Trends Neurosci.

    (1986)
  • ShannonM. et al.

    5HT1 and 5HT2 serotonin receptor binding properties of the hallucinogen 1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane

    Eur. J. Pharmac.

    (1984)
  • TaiwoY.O. et al.

    The contribution of training to sensitivity in the nociceptive paw-withdrawal test

    Brain Res.

    (1989)
  • TaiwoY.O. et al.

    Hyperalgesia onset latency suggests a hierarchy of action

    Brain res.

    (1987)
  • TaiwoY.O. et al.

    Characterization of the arachidonic acid metabolites mediating bradykinin and noradrenaline hyperalgesia

    Brain Res.

    (1988)
  • TaiwoY.O. et al.

    Prostaglandin effects after elimination of indirect hyperalgesic mechanisms in the skin of the rat

    Brain Res.

    (1989)
  • TaiwoY.O. et al.

    Direct cutaneous hyperalgesia induced by adenosine

    Neuroscience

    (1990)
  • TaiwoY.O. et al.

    Mediation of serotonin hyperalgesia by the cAMP second messenger system

    Neuroscience

    (1992)
  • WatlingK.J. et al.

    [3H] Quarternized ICS 205-930 labels 5-HT3 receptor binding sites in the rat brain

    Eur. J. Pharmac.

    (1988)
  • ArvidssonL.E. et al.

    8-Hydroxy-2-(di-n-propylamino) tetralin a new centrally acting 5-hydroxytryptamine receptor agonist

    J. med. Chem.

    (1981)
  • AwoutersF.

    The pharmacology of ketanserin, the first selective serotonin S2-antagonist

    Drug Dev. Res.

    (1985)
  • BeckP.W. et al.

    Bradykinin and serotonin effects on various types of cutaneous nerve fibers

    Pflu¨gers Arch.

    (1974)
  • Cited by (0)

    *

    Present address: The Proctor and Gamble Co., Cincinnati, OH 45239-8707, U.S.A.

    View full text